Advanced Pancreatic Cancer Clinical Trial
Official title:
A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: - Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer. - Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer. Participants will be asked to complete the study procedures: - Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B. - Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. - Complete the study procedures specified in the protocol, which is guided by researchers.
This is a phase II, open-label study to evaluate safety, tolerability, pharmacokinetics (PK), and clinical benefit of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT03662035 -
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT05085548 -
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04137536 -
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT04617067 -
Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04469556 -
Pancreatic Adenocarcinoma Signature Stratification for Treatment
|
Phase 2 | |
Recruiting |
NCT04104672 -
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT05100329 -
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02101580 -
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06329947 -
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
|
Phase 2 | |
Recruiting |
NCT02135822 -
Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04803851 -
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03415802 -
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT05162118 -
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04643405 -
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03889795 -
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
|
Phase 1 | |
Completed |
NCT01303172 -
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06422156 -
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04931381 -
Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT04482257 -
Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.
|
Phase 1 |